Amicus Therapeu…
ProfileJobs

Amicus Therapeutics

Suggest Edit
    • Healthclinicspharma
    Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules to restore or improve biological activity in cells by selectively binding to misfolded, unstable proteins caused by genetic mutations. This technology represents a novel, next-generation approach to the management of human genetic diseases and offers the potential to improve treatment options for many patients. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. The company believes pharmacological chaperone technology has broad applicability and expects to expand the portfolio to include other diseases of neurodegeneration, metabolic diseases, and oncology. Founded in 2002, Amicus has assembled an outstanding leadership team that includes scientific, medical, regulatory, and business professionals with successful track records of developing and bringing to market drugs for genetic diseases. Amicus continues to develop its pharmacological chaperone technology and has built a significant intellectual property portfolio along with its robust clinical and preclinical pipeline. Amicus has a fast-paced, high-energy, entrepreneurial team environment where employees are encouraged to be innovative and resourceful. Amicus seeks high-caliber, talented individuals with a passion to succeed.
    Show more
    Revenue(FY, 2017)
    $36.9 M
    Market capitalization(2018-04-23)
    $2.1 B
    Type
    Public
    HQ
    Cranbury Township, US
    Founded
    2002
    Size (employees)
    263 (est)
    Website
    amicusrx.com
    Amicus Therapeutics was founded in 2002 and is headquartered in Cranbury Township, US
    Report incorrect company information

    Key People/Management at Amicus Therapeutics

    William D. Chip Baird

    William D. Chip Baird

    Chief Financial Officer
    Bradley L Campbe

    Bradley L Campbe

    Chief Operating Officer
    Jeffrey P Castelli

    Jeffrey P Castelli

    Vice President
    Enrique Diloné

    Enrique Diloné

    Vice President
    Jay A Barth

    Jay A Barth

    Chief Medical Officer
    Hung Do

    Hung Do

    Senior Vice President

    Amicus Therapeutics Office Locations

    Amicus Therapeutics has offices in Denham, Munich, Cranbury Township, Puteaux and in 1 other location
    Cranbury Township, US (HQ)
    1 Cedar Brook Drive
    Puteaux, FR
    Tour Défense 2000
    Show all (5)
    Report incorrect company information

    Amicus Therapeutics Financials and Metrics

    Amicus Therapeutics Financials

    Amicus Therapeutics's revenue was reported to be $36.93 m in FY, 2017
    USD

    Revenue (FY, 2017)

    		36.9 m

    Gross profit (FY, 2017)

    		30.7 m

    Gross profit margin (FY, 2017), %

    		83.1%

    EBIT (FY, 2017)

    		(442 m)

    Market capitalization (23-Apr-2018)

    		2.1 b

    Cash (31-Dec-2017)

    		49.1 m
    Amicus Therapeutics's current market capitalization is $2.1 b.
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Revenue

    		122.2 m1.2 m5 m36.9 m

    Revenue growth, %

    		(99%)(100%)

    Cost of goods sold

    		833 k6.2 m

    Gross profit

    		4.1 m30.7 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

    Revenue

    		39 k456 k475 k293 k456 k475 k293 k

    Cost of goods sold

    		344 k775 k1.8 m

    General and administrative expense

    		4.6 m5.2 m4.8 m5.3 m6.4 m8.3 m15.4 m15.7 m19.3 m17.5 m19.1 m

    R&D expense

    		10.1 m10 m10 m12 m16.1 m17.2 m21 m23.4 m18.3 m32.5 m30.9 m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Cash

    		43.6 m24.1 m69.5 m187 m49.1 m

    Accounts Receivable

    		1.3 m9.5 m

    Inventories

    		5.5 m2.9 m2.6 m3.4 m4.6 m

    Current Assets

    		88.3 m154.6 m216.6 m340.1 m392 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Cash

    		30 m27.5 m41.9 m19.7 m28.8 m249 m19.4 m23.5 m63.7 m33.1 m44.8 m37.4 m64.1 m

    Accounts Receivable

    		864 k1.9 m3.8 m6 m

    Inventories

    		194 k3.3 m3.7 m3.9 m7.3 m

    Current Assets

    		64.3 m73.5 m79.4 m87.2 m151.3 m365 m240.1 m168.5 m217.7 m221.7 m296.2 m241 m431 m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    		(59.6 m)(68.9 m)(132.1 m)(200 m)(284 m)

    Depreciation and Amortization

    		1.7 m1.5 m1.8 m3.2 m3.6 m

    Inventories

    		(3.2 m)2.3 m308 k(3.7 m)(897 k)

    Accounts Payable

    		6.2 m15.5 m7.1 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Net Income

    		(47.4 m)(15.9 m)(30.6 m)(47.7 m)(24.3 m)(51.4 m)(89.2 m)(43.7 m)(94.7 m)(141.4 m)(55 m)(103.1 m)(214.8 m)

    Depreciation and Amortization

    		1.3 m412 k808 k1.2 m508 k861 k1.3 m673 k1.4 m2.3 m823 k1.6 m

    Inventories

    		(207 k)(3.5 m)(243 k)(351 k)7.3 m

    Accounts Payable

    		(679 k)(987 k)(155 k)1.2 m(551 k)459 k14.1 m(9.8 m)(8.2 m)(2.9 m)(1.3 m)
    show all
    USDY, 2017

    Revenue/Employee

    		140.4 k

    Financial Leverage

    		1.8 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    BTG
    Health - Public
    Durect
    Health - Public
    Affimed N.V.
    Health - Public
    Sucampo Pharmaceuticals
    Health - Public
    Compare competitors
    Download PDF